IBO
Price
$3.80
Change
-$0.22 (-5.47%)
Updated
Oct 22, 04:58 PM (EDT)
Capitalization
34.35M
15 days until earnings call
Intraday BUY SELL Signals
PCSA
Price
$1.86
Change
+$0.10 (+5.68%)
Updated
Oct 22 closing price
Capitalization
5.2M
14 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IBO vs PCSA

IBO vs PCSA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
IBO vs. PCSA commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IBO is a Hold and PCSA is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for IBO with price predictions
Oct 22, 2026

Momentum Indicator for IBO turns negative, indicating new downward trend

IBO saw its Momentum Indicator move below the 0 level on September 25, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator turned negative. In 36 of the 39 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for IBO turned negative on September 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 15 similar instances when the indicator turned negative. In 11 of the 15 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.

IBO moved below its 50-day moving average on September 24, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for IBO crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 8 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

IBO broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for IBO entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IBO's RSI Oscillator exited the oversold zone, 7 of 9 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 23 of 28 cases where IBO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

Following a +31.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBO advanced for three days, in 72 of 91 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 8 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.190) is normal, around the industry mean (2.973). P/E Ratio (0.362) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (1111.111) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. IBO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for PCSA with price predictions
Oct 22, 2026

PCSA's RSI Indicator recovers from oversold territory

The RSI Oscillator for PCSA moved out of oversold territory on October 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 47 similar instances when the indicator left oversold territory. In 43 of the 47 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on PCSA as a result. In 70 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.

The Moving Average Convergence Divergence (MACD) for PCSA just turned positive on October 12, 2026. Looking at past instances where PCSA's MACD turned positive, the stock continued to rise in 40 of 46 cases over the following month. The odds of a continued upward trend are 87%.

Following a +5.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where PCSA advanced for three days, in 188 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

PCSA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCSA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for PCSA entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-16.373) is normal, around the industry mean (2.973). P/E Ratio (2.862) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 60 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. PCSA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCSA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
IBO vs PCSA: Fundamental Ratings
IBO
PCSA
OUTLOOK RATING
1..100
9748
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
12
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8100
PRICE GROWTH RATING
1..100
9084
P/E GROWTH RATING
1..100
7560
SEASONALITY SCORE
1..100
307

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PCSA's Valuation (12) in the null industry is significantly better than the same rating for IBO (81). This means that PCSA’s stock grew significantly faster than IBO’s over the last 12 months.

PCSA's Profit vs Risk Rating (100) in the null industry is in the same range as IBO (100). This means that PCSA’s stock grew similarly to IBO’s over the last 12 months.

IBO's SMR Rating (8) in the null industry is significantly better than the same rating for PCSA (100). This means that IBO’s stock grew significantly faster than PCSA’s over the last 12 months.

PCSA's Price Growth Rating (84) in the null industry is in the same range as IBO (90). This means that PCSA’s stock grew similarly to IBO’s over the last 12 months.

PCSA's P/E Growth Rating (60) in the null industry is in the same range as IBO (75). This means that PCSA’s stock grew similarly to IBO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IBOPCSA
RSI
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
85%
MACD
ODDS (%)
Bearish Trend 1 day ago
73%
Bullish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
19%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 1 day ago
84%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (IBO: $4.02 vs. PCSA: $1.86)
Brand notoriety: IBO and PCSA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IBO: 147% vs. PCSA: 12%
Market capitalization -- IBO: $34.35M vs. PCSA: $5.2M
IBO [@Biotechnology] is valued at $34.35M. PCSA’s [@Biotechnology] market capitalization is $5.2M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IBO’s FA Score shows that 1 FA rating(s) are green while PCSA’s FA Score has 1 green FA rating(s).

  • IBO’s FA Score: 1 green, 4 red.
  • PCSA’s FA Score: 1 green, 4 red.
According to our system of comparison, PCSA is a better buy in the long-term than IBO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IBO’s TA Score shows that 3 TA indicator(s) are bullish while PCSA’s TA Score has 5 bullish TA indicator(s).

  • IBO’s TA Score: 3 bullish, 7 bearish.
  • PCSA’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, PCSA is a better buy in the short-term than IBO.

Price Growth

IBO (@Biotechnology) experienced а +18.12% price change this week, while PCSA (@Biotechnology) price change was +10.71% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

IBO is expected to report earnings on Nov 06, 2026.

PCSA is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
IBO
Daily Signal:
Gain/Loss:
PCSA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

IBO and

Correlation & Price change

A.I.dvisor tells us that IBO and PCSA have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IBO and PCSA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBO
1D Price
Change %
IBO100%
-5.47%
PCSA - IBO
32%
Poorly correlated
+5.68%
INDP - IBO
27%
Poorly correlated
-5.38%
LPCN - IBO
27%
Poorly correlated
-8.75%
IVVD - IBO
24%
Poorly correlated
-4.57%
LIMN - IBO
24%
Poorly correlated
-0.32%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MMSI93.942.54
+2.78%
Merit Medical Systems
XPER5.210.05
+0.97%
Xperi
DASH185.941.49
+0.81%
DoorDash
DAIO2.49-0.10
-3.86%
Data I/O Corp
TMC2.47-0.18
-6.79%
TMC the metals company